MDXG - MiMedx Group, Inc. Stock Price, Fair Value and News

$6.95+0.23 (+3.42%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MDXG Price Action

Last 7 days

1.0%

Last 30 days

-7.6%

Last 90 days

-2.0%

Trailing 12 Months

-27.2%

MDXG RSI Chart

MDXG Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

25.21

Price/Sales (Trailing)

2.62

EV/EBITDA

16.23

Price/Free Cashflow

15.18

MDXG Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MDXG Fundamentals

MDXG Revenue

Revenue (TTM)

393.4M

Rev. Growth (Yr)

35.3%

Rev. Growth (Qtr)

15.33%

MDXG Earnings

Earnings (TTM)

40.8M

Earnings Growth (Yr)

106.89%

Earnings Growth (Qtr)

74.13%

MDXG Profitability

EBT Margin

14.16%

Return on Equity

17.09%

Return on Assets

12.8%

Free Cashflow Yield

6.59%

MDXG Investor Care

Shares Dilution (1Y)

0.79%

Diluted EPS (TTM)

0.27

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	352.4M	363.8M	393.4M	0
2024	334.5M	340.5M	342.8M	348.9M
2023	280.6M	295.0M	309.0M	321.5M
2022	240.9M	239.7M	244.3M	267.8M
2021	246.5M	261.0M	259.8M	242.0M
2020	294.4M	280.6M	256.1M	248.2M
2019	341.5M	313.5M	315.4M	299.3M
2018	336.5M	351.4M	354.4M	359.1M
2017	260.4M	283.6M	303.2M	321.1M
2016	199.9M	211.6M	227.0M	245.0M
2015	139.4M	159.5M	175.0M	187.3M
2014	67.2M	79.2M	96.6M	118.2M
2013	34.9M	43.5M	51.7M	59.2M
2012	10.4M	13.4M	19.2M	27.1M
2011	2.5M	4.3M	6.0M	7.8M
2010	0	0	0	788.9K

Get all data in R, Python etc through our Historical Stock Data APIs

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

CEO	Mr. Joseph H. Capper
WEBSITE	mimedx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	867

MiMedx Group, Inc. Frequently Asked Questions

What is the ticker symbol for MiMedx Group, Inc.? What does MDXG stand for in stocks?

MDXG is the stock ticker symbol of MiMedx Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiMedx Group, Inc. (MDXG)?

As of Wed Dec 03 2025, market cap of MiMedx Group, Inc. is 1.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers.

Is MiMedx Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether MDXG is over valued or under valued. Whether MiMedx Group, Inc. is cheap or expensive depends on the assumptions which impact MiMedx Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDXG.

What is MiMedx Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MDXG's PE ratio (Price to Earnings) is 25.21 and Price to Sales (PS) ratio is 2.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDXG PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MiMedx Group, Inc.'s stock?

In the past 10 years, MiMedx Group, Inc. has provided -0.025 (multiply by 100 for percentage) rate of return.